Ever since the approval of Stage IV solid tumor of the dendritic cells therapy by the Taiwan TFDA in May, Ever Supreme had once again collaborated with the China Medical University Hospital, and received approval on "Stages I o III after ineffective conventional treatment" by DC therapy in September. Ever Supreme has performed outstandingly under RGSCTT; it is the first biotechnology company in Taiwan to be approved offer dendritic cell technology that is used on all stages of cancer patients. More medical institutions have joined together to apply for RGSCTT to promote patient welfare, and to benefit the public health.
.jpg)